The following individuals have expressed opinions on iCo Therapeutics and may be contacted directly for copies of their reports. Please view our Cautionary Notes regarding this list.

Publication Name Contact
Emerging drug developer in attractive ocular disease space Douglas W. Loe, Ph.D, MBA, Versant Partners
(416) 964-4430
The Next Wave (Dundee Biotech) David Martin, PhD, MBA, Dundee Securities Dundee has since been acquired by Scotiabank.